Acquired by Occulo in April 2018, Stealth Biologics, LLC had been a specialized service company employing an advanced Deimmunized By Design® computational platform to assess and mitigate immunogenicity risk for biopharma clients. Engaging Stealth early in development programs had been designed to de-risk therapeutic development and enable effective prioritization of lead candidates. The firm's pre-acqusition description defined the firm as redesigning and reengineering therapeutic proteins to evade immune recognition. The firm's approach integrated advanced computational models, protein design algorithms, and protein engineering methodologies to develop optimized therapeutic candidates that are less immunogenic but functionally equivalent to -- or better than -- natures own biomolecules.Stealth management acknowledged their technology built on a several year academic collaboration, funded by the NIH and NSF, that had extended their protein deimmunization algorithms for commercial application.
